Prevalence of microbial urinary tract infection associated with COVID-19 in hospitalized patients: An example from Biskra, Algeria
Keywords:
COVID-19, Microbes, Urinary Tract InfectionAbstract
Objective: To explore and contribute to the understanding of urinary tract infections (UTIs) associated with COVID-19, a frequent yet underreported complication.
Methods: This was a retrospective study carried out on 1,620 patients suspected to have a UTI, who consulted at Hakim Saadane Hospital of Biskra (Algeria) during the year 2021. Our attention was on the refined population with a positive cytobacteriological examination of urine and COVID-19 admission, where an examination of microbial prevalence was done.
Findings: Statistical analysis of our data showed three main detected groups: Gram-negative bacteria, represented mainly by Enterobacteriales and Pseudomonas aeruginosa; Gram-positive bacteria, including Staphylococcus aureus; and a Candida group, mostly constituted by Candida albicans and Candida spp. UTI in COVID-19 patients was characterized by a significant decrease (p<0.05) in Gram-positive bacterial prevalence and a clear increase in Candida prevalence.
Conclusions: More studies must be conducted on UTI superinfections with COVID-19 to prevent severe outcomes and establish the ideal treatment.
Downloads
References
Garcia-Bustos V, Renau Escrig AI, Campo López C et al. Prospective cohort study on hospitalised patients with suspected urinary tract infection and risk factors por multidrug resistance. Sci Rep 2021; 11:1-11. https//:doi.org/10.1038/s41598-021-90949-2
Kyriakopoulos C, Gogali A, Exarchos K et al. Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave in Greece. Respiration 2021; 100:588-593. http//:doi.org/10.1159/000515323.
Cai T, Tascini C, Novelli A et al. The Management of Urinary Tract Infections during the COVID-19 Pandemic: What Do We Need to Know? 2022; Urol 2:55-64. https://doi.org/10.3390/uro2010008
Grinbaum RS, Kiffer CRV. Bacterial infections in COVID-19 patients: a review. Rev Assoc Med Bra (1992) 2021; (12):1863-1868. https://doi.org/10.1590/1806-9282.20210812
Yang L, Han Y, Nilsson-Payant BE et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 2020; 27(1):125-136. https://doi.org/10.1016/j.stem.2020.06.015
Pollán BD, López GVG, Clemente PMG et al. Urinary Tract Infections in Hospitalized COVID-19 Patients, What’s Up, Doc?. J clin med 2022; 11(1815): 1-9. http://doi.org/10.3390/jcm11071815
Nag VL, Kaur N. Superinfections in COVID-19 Patients: Role of Antimicrobials. Dubai Med J 2021; 4:117-126. https://doi.org/10.1159/000515067
Karaba SM, Jones G, Helsel T et al. Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open Forum Infect Dis 2020; 8:1-7. http://doi.org/10.1093/ofid/ofaa578
Laethem JV, Wuyts SCM, Pierreux J et al. Presumed Urinary Tract Infection in Patients Admitted with COVID-19: Are We Treating Too Much?. Antibiotics (Basel) 2021; 10(12): 1493. http://doi.org/10.3390/antibiotics10121493
Magill SS, Edwards JR, Bamberg W et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198-1208. http://doi.org/10.1056/NEJMoa1306801
Garcia-Vidal C, Sanjuan G, Moreno-Garcia E et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27(1): 83-88. http://doi.org/10.1016/j.cmi.2020.07.041
Sun EF. Patient with Pseudomonas aeruginosa vertebral osteomyelitis presenting with back pain on a telephonic encounter due to COVID-19. Clin Case Stud Rep 2020; 3:1-2. http://doi.org/10.15761/CCSR.1000144
Said KB, Alsolami A, Moussa S et al. COVID-19 Clinical Profiles and Fatality Rates in Hospitalized Patients Reveal Case Aggravation and Selective Co-Infection by Limited Gram-Negative Bacteria. Int J Environ Res Public Health 2022; 19, 5270: 1-16. http://doi.org/10.3390/ijerph19095270
Marcus RJ, Post JC, Stoodley P et al. Biofilms in nephrology. Expert Opin Biol Ther 2008; 8(8):1159-1166. http://doi.org/10.1517/14712598.8.8.1159
Zia M, Goli M. Predisposing factors of important invasive fungal coinfections in COVID-19 patients: a review article. J Int Med Res 2020; 49(9): 1-11. http://doi.org/10.1517/14712598.8.8.1159
Roudbary M, Kumar S, Kumar A, Cernakova L, Nikoomanesh F, Rodrigues CF. Overview on the prevalence of fungal infections, immune response, and microbiome role in COVID-19 patients. J Fungi (Basel) 2021; 7(9): 720-32. http://doi.org/10.3390/jof7090720
Miftode IL, Nastase EV, Miftode RS et al. Insights into multidrug-resistant K. pneumoniae urinary tract infections: From susceptibility to mortality. Exp Ther Med 2021; 22(4):1086-94. http://doi.org/10.3892/etm.2021.10520
Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J. A. European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin Microbiol Infect 2021; 7:523-531. http://doi.org/10.1046/j.1198-743x.2001.00326.x
Bhatt PJ, Shiau S, Brunetti L et al. Risk factors and outcomes of hospitalized patients with severe coronavirus disease 2019 (COVID-19) and secondary bloodstream infections: a multicenter case-control study. Clin Infect Dis 2021; 72(12): 995-1003. http://doi.org/10.1093/cid/ciaa1748
Bajpai KV, Khan I, Shukla S et al. Invasive Fungal Infections and Their Epidemiology: Measures in the Clinical Scenario. Biotechnol Bioprocess Eng 2019; 24:436-444.
Kim SJ, Ryu JH, Kim YB, Yang SO. Management of Candida Urinary Tract Infection in the Elderly. Urogenital Tract Infection 2019; 14(2):33-41. https://doi.org/10.14777/uti.2019.14.2.33
Coker C, Poore CA, Li X, Mobley HL. Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect 2000; 2(12):1497-1505. http://doi.org/10.1016/s1286-4579(00)01304-6.
Liu H, Zhu J, Hu Q, Rao X. Morganella morganii, a non-negligent opportunistic pathogen. Int J Infect Dis 2016; 50: 10-17. http://doi.org/10.1016/j.ijid.2016.07.006
Zuo T, Liu Q, Zhang F et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut 2020; 70:276-284. http://doi.org/10.1136/gutjnl-2020-322294
Lagunas-Rangel FA. Antimicrobial susceptibility profiles of bacteria causing urinary tract infections in Mexico: Single-centre experience with 10 years of results. J Glob Antimicrob Resist 2018; 14:90-94. http://doi.org/10.1016/j.jgar.2018.03.004
Collin SM, Shetty N, Guy R et al. Group B Streptococcus in surgical site and non-invasive bacterial infections worldwide: A systematic review and meta-analysis. Int J Infect Dis 2019; 83:116-129. http://doi.org/10.1016/j.ijid.2019.04.017
Mohanty S, Purohit G, Rath S, Seth RK, Mohanty RR. Urinary tract infection due to Group B Streptococcus: A case series from Eastern India. Clin Case Rep 2021; 9: 1-6. http://doi.org/10.1002/ccr3.4885
Flores-Mireles AL, Pinkner JS, Caparon MG, Hultgren SJ. EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci Transl Med 2014; 6(254): ra127. http://doi.org/10.1126/scitranslmed.3009384
Pintado V, Ruiz-Garbajosa P, Escudero-Sanchez R et al. Carbapenemase-producing Enterobacterales infections in COVID-19 patients. Infect Dis 2022; 54(1): 36-45. http://doi.org/10.1080/23744235.2021.1963471
Self WH, Wunderink RG, Williams DJ et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis 2016; 63(3): 300-309. http://doi.org/10.1093/cid/ciw300
Kulkarni D, Wang X, Sharland E, Stansfield D, Campbell H, Nair H. The global burden of hospitalisation due to pneumonia caused by Staphylococcus aureus in the under-5 years children: A systematic review and meta-analysis. eClin Med 2022; 44: 101267. http://doi.org/10.1016/j.eclinm.2021.101267
Hannoune D, Boughoufalaha A, Hellala H et al. COVID-19 : Situation épidémiologique et évolution en Algérie. Revue Algérienne d’allergologie 2020; 05(01): 2543-3555.
Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. J Int Med Res 1991; 19(6):433-445. http://doi.org/10.1177/030006059101900602
Ikemoto K, Shinya Kobayashi S, Haranosono Y et al. Contribution of anti-inflammatory and antivirulence effects of azithromycin in the treatment of experimental Staphylococcus aureus keratitis. BMC Ophthalmol 2020; 20(89): 1-7. http://doi.org/10.1186/s12886-020-01358-4
Cheng K, He M, Shu Q, Wu M, Chen C, Xue Y. Analysis of the risk factors for nosocomial bacterial infection in patients with COVID-19 in a tertiary hospital. Risk Manag Healthc Policy 2020; 13: 2593-2599. http://doi.ogg/10.2147/RMHP.S277963
Estrada ADB, Parra JC, Carracedo EF et al. Inadequate use of antibiotics in the COVID-19 era: Effectiveness of antibiotic therapy. BMC Infect Dis 2021; 21, 1144-59. http://doi.org/10.1186/s12879-021-06821-1
Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 2014; 14:13. http://doi.org/10.1186/1471-2334-14-13
Liu Y, Li Y, Xu D, Zhang J, Peng Z. Severe COVID-19: Immunosuppression or Hyperinflammation? Shock 2021; 56(2):188-199. http://doi.org/10.1097/SHK.0000000000001724
Sacar S, Turgut H, Kaleli I et al. Poor hospital infection control practice in hand hygiene, glove utilization, and usage of tourniquets. Am J Infect Control 2006; 34(9): 606-609. http://doi.org/10.1016/j.ajic.2006.02.006
Fehér A, Szarvas Z, Lehoczki A, Fekete M, Fazekas-Pongor V. Co-infections in COVID-19 patients and correlation with mortality rate. Minireview. Physiol Int 2022; 109(1): 1-8. http://doi.org/10.1556/2060.2022.00015
Downloads
Published
How to Cite
Issue
Section
License
Copyright and Licensing
For all articles published in Atena Journals, copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper credit.
Reproducing Published Material from other Publishers
It is absolutely essential that authors obtain permission to reproduce any published material (figures, schemes, tables or any extract of a text) which does not fall into the public domain, or for which they do not hold the copyright. Permission should be requested by the authors from the copyrightholder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyrightholder).
Permission is required for:
- Your own works published by other Publishers and for which you did not retain copyright.
- Substantial extracts from anyones' works or a series of works.
- Use of Tables, Graphs, Charts, Schemes and Artworks if they are unaltered or slightly modified.
- Photographs for which you do not hold copyright.
Permission is not required for:
- Reconstruction of your own table with data already published elsewhere. Please notice that in this case you must cite the source of the data in the form of either "Data from..." or "Adapted from...".
- Reasonably short quotes are considered fair use and therefore do not require permission.
- Graphs, Charts, Schemes and Artworks that are completely redrawn by the authors and significantly changed beyond recognition do not require permission.
Obtaining Permission
In order to avoid unnecessary delays in the publication process, you should start obtaining permissions as early as possible. If in any doubt about the copyright, apply for permission. Atena Journals cannot publish material from other publications without permission.
The copyright holder may give you instructions on the form of acknowledgement to be followed; otherwise follow the style: "Reproduced with permission from [author], [book/journal title]; published by [publisher], [year].' at the end of the caption of the Table, Figure or Scheme.
